Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
about
Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial.Shades of grey: the conundrum of implantable defibrillators in individuals with advanced CKDDecreased systolic blood pressure is associated with increased risk of all-cause mortality in patients with type 2 diabetes and renal impairment: A nationwide longitudinal observational study of 27,732 patients based on the Swedish National DiabetesChronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
P2860
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cause of Death in Patients Wit ...... With Aranesp Therapy (TREAT).
@ast
Cause of Death in Patients Wit ...... With Aranesp Therapy (TREAT).
@en
type
label
Cause of Death in Patients Wit ...... With Aranesp Therapy (TREAT).
@ast
Cause of Death in Patients Wit ...... With Aranesp Therapy (TREAT).
@en
prefLabel
Cause of Death in Patients Wit ...... With Aranesp Therapy (TREAT).
@ast
Cause of Death in Patients Wit ...... With Aranesp Therapy (TREAT).
@en
P2093
P2860
P50
P1476
Cause of Death in Patients Wit ...... s With Aranesp Therapy (TREAT)
@en
P2093
Ajay K Singh
Akshay S Desai
Andrew S Levey
Brian Claggett
Eldrin F Lewis
Jiankang Liu
L Howard Hartley
Marc A Pfeffer
Peter Finn
Peter Ivanovich
P2860
P304
P356
10.1053/J.AJKD.2015.02.324
P577
2015-04-29T00:00:00Z